Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

248 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2022-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The clinical symptoms of non transfusion dependent non severe aplastic anemia (NSAA) are often lighter than that of severe aplastic anemia. Clinical observation is often used and the treatment should be given according to the follow-up results of peripheral blood routine and the survival condition of the patients. In recent years, a number of studies at home or abroad have tended to intervene earlier. The risk of observation and waiting for disease progression is higher. Early immunosuppression should be considered. For the treatment of non transfusion dependent non severe aplastic anemia, the commonly used treatment regimen is androgen combined with CSA. But the investigators find that Levamisole hydrochloride (LMS) as a commonly used immunomodulatory drugs may be helpful to improving immune disorder symptoms in NSAA patients. Therefore,the investigators are conducting a prospective, randomized controlled study to compare the rate, side effects and long-term survival in non transfusion dependent patients with NSAA between the androgen+CSA group and the androgen+CSA+LMS group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

NCT05660785

Non Severe Aplastic Anemia Untreated

COMPLETED PHASE2

Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA

NCT06525948

Aplastic Anemia Transfusion-dependent Anemia

NOT_YET_RECRUITING PHASE4

A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA

NCT06535685

Aplastic Anemia

NOT_YET_RECRUITING PHASE4

Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study

NCT06964971

Transfusion-dependent Non-severe Aplastic Anemia

NOT_YET_RECRUITING NA

Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia

NCT07010237

Sever Aplastic Anaemia Elderly (People Aged 65 or More) Immunosuppressive Treatment

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aplastic Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

experimental group

the patients treated with levamisole hydrochloride 150mg qod +androgens 80mg qd+cyclosporins 3-5mg/kg\*d at least for one year

Group Type EXPERIMENTAL

levamisole hydrochloride

Intervention Type DRUG

levamisole hydrochloride take orally 150mg qod

Androgens

Intervention Type DRUG

Androgens take orally 80mg qd

Cyclosporins

Intervention Type DRUG

Cyclosporines take orally 3-5mg/kg\*d qd

control group

the patients treated without levamisole hydrochloride，but androgens 80mg qd+cyclosporins 3-5mg/kg\*d at least for one year

Group Type OTHER

Androgens

Intervention Type DRUG

Androgens take orally 80mg qd

Cyclosporins

Intervention Type DRUG

Cyclosporines take orally 3-5mg/kg\*d qd

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

levamisole hydrochloride

levamisole hydrochloride take orally 150mg qod

Intervention Type DRUG

Androgens

Androgens take orally 80mg qd

Intervention Type DRUG

Cyclosporins

Cyclosporines take orally 3-5mg/kg\*d qd

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

levamisole

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. All the patients meet a NSAA diagnostic criteria, and agree the immunosuppressive therapy. Diagnoses reference to The diagnostic and therapeutic criteria for hematologic diseases（Zhang Zhinan 2007）, and The diagnosis and treatment of aplastic anemia（2016 UK guidelines）
2. 18-70years old, male or female
3. Liver and kidney function: the blood bilirubin is less than or equal to 2mg/dL (35 mol/L), AST/ALT in the upper limit of the normal value below 2 times, blood inosine is less than or equal to 177 umol/L.
4. Heart function is normal: EF\>50%.
5. No serious lung infection.
6. All cases had no history of cancer and chemotherapy history, immunology therapy. The control group without hematologic diseases, lupus or other immune disfunctions, allergic disease, Fanconi anemia.
7. Consent signed by patients or their families.

Exclusion Criteria

1. Congenital hematopoietic failure, Fanconi anemia, or combined with bone marrow hyperplasia, leukemia, multiple myeloma, giant cell anemia, paroxysmal nocturnal hemoglobin or other blood diseases.
2. The HBV DNA copy number is greater than 1000/ml or the serum hepatitis B virus is not clear.
3. Serum bilirubin \> 2mg/dL (35 umol/L); ALT or AST \> 2 times the normal value of the upper limit; alkaline phosphatase \> 3 times the upper limit of the normal value; serum creatinine \> 177 mol/L.
4. HIV positive.
5. Other serious diseases that may limit the patient to participate in the study (e.g., the progressive infection, incontrollable diabetes, severe cardiac insufficiency or angina pectoris, etc.)
6. Conditions are not suitable for immunosuppressive therapy.
7. Pregnant or lactating women.
8. Can not understand or follow the research program.
9. Patients under 16 years of age.
10. Patients with a history of cancer, chemotherapy, or radiation therapy, immune system diseases or allergic diseases.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No